La Merie, Feb 2012
on targets, product categories and R&D phases
- Ideal for competitoranalysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing
Espicom Business Intelligence Ltd, April 2010, Pages: 145
Proportions of Cancer Indications (2008)
Incidence of Major Cancer Indications (2008 and 2015)
Incidence and Mortality Comparisons (2008)
Sales of VEGF Pathway Inhibitors (2015)
Competitor Ratio Analysis Scores
GlobalData, Sep 2010, Pages: 58
and emerging trends. Pipeline candidates fall under major therapeutic classes such as of DNA synthesis inhibitors, HDACinhibitors, DNA methyltransferase inhibitors and Aurora kinase inhibitors, CD33 antigen
GlobalData, Dec 2010, Pages: 49
classes such as mTOR inhibitors, Tyrosine kinase inhibitors, HDACinhibitors, TNF-alpha inhibitors and Heparanase inhibitors.
- Analysis of the current and future competition in the global Liver cancer
GlobalData, Dec 2010, Pages: 50
of action being developed and emerging trends. Pipeline candidates fall under different mechanisms of actions, which include hemopoietic growth factor, histone deacetylase (HDAC) inhibitors, hepatocyte growth
GlobalData, Sep 2011, Pages: 41
is also involved in partnership programs under which it offers three product candidates, namely, EVP-0334 (HDACinhibitor), Mocetinostat (MGCD0103, HDACinhibitor)) and kinase inhibitors. The company has
GlobalData, Sep 2011, Pages: 78
polymerase inhibitor, histone deacetylase (HDAC) inhibitor, dihydrofolate reductase inhibitor and Eg5 Inhibitor.
- Analysis of the current and future competition in the seven key countries ALL therapeutics
GlobalData, March 2011, Pages: 80
key markets. Pipeline candidates fall under major therapeutic classes such as Anti-CD20 Mab, Bcl-2 Inhibitors, CDK Inhibitors, Multi TKIs, Immunomodulators, Phosphodiesterase Inhibitors, HDACInhibitors
GlobalData, Aug 2011, Pages: 43
strategic alliance with Servier, for the research, development, and commercialization of Pharmacyclics' PCI-24781, an orally active, small molecule inhibitor of Pan HDAC enzymes, for the treatment of solid
Bioseeker, Dec 2006, Pages: 550
inhibitors, Anti-angiogenic and vascular targeting agents, Immunostimulators, Antibodies and Vaccines
- Progress analysis of major cancer indications for respective targeting strategy, including players, drugs
GlobalData, Sep 2011, Pages: 38
: 4SC Reports Q2 2010 Results
May 26, 2010: Phase Ii Hodgkin Lymphoma Study With HdacInhibitor Resminostat Advances Into The Second Recruitment Stage
May 11, 2010: 4SC Reports Q1 2010 Results
Apr
Espicom Business Intelligence Ltd, April 2008, Pages: 245
. Of these new agents in development, we highlight the HDACinhibitors and Hsp90 inhibitors as being among the most interesting, though much development remains in the early stages.
Among the products evaluated
Bioseeker, Jan 2007, Pages: 750
in earlier-stage cancer could be more effective
4517 Discontinued radiosensitizer
4518 Improvement in chemoradiotherapy
4519 Progress on HDACinhibitor
4520 Progress Analysis Carboxyamidotriazole
4521
